Drugstore Blog News

WHAT: The 2010 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) brings together leading allergists and immunologists from in a circle the earth.

WHO: Scientists supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, will be presenting their latest research findings at the AAAAI Annual Meeting. For more than 60 years, NIAID has supported allergy and immunology research at U.S. and international institutions and conducted studies within its have laboratories to improve the soundness of millions of the many the crowd.

WHEN: February 26 to March 2, 2010

WHERE: Ernest N. Morial Convention Center, New Orleans, La.

Below are advance summaries of select presentations describing NIAID-funded research.

Findings from the Inner-City Anti-IgE Therapy in spite of Asthma Study

Asthma affects as many since 20 the public Americans, but it disproportionately affects children – especially African-American and Hispanic children – who live in inner-city environments. Over the past two decades, NIAID has supported careful search programs aimed at developing asthma interventions tailored to children mode of life in inner-city areas. The Inner-City Asthma Consortium (ICAC), a network of eight clinical and couple basic careful search sites nationwide, is a captious section of that effort. ICAC investigators designed and conducted the Inner-City Anti-IgE Therapy for Asthma (ICATA) study in which children by gentle to accurate asthma were given omalizumab, a monoclonal antibody that targets immunoglobulin E (IgE), an antibody that triggers allergic reactions and inflammation in the lungs. The design of this study was to determine whether or not adding omalizumab to the asthma treatment directed through the National Asthma Education and Prevention Program Guidelines (www.nhlbi.nih.gov/guidelines/asthma/) provides additional benefit beyond guidelines-based asthma therapy alone. Three ICAC investigators will consider the results of the ICATA study and novel insights the study provides regarding the role of allergy in asthma exacerbations.

Title: Symposium: Findings from the Inner-City Anti-IgE Therapy for Asthma (ICATA)
Presenters: William Busse, M.D., University of Wisconsin-Madison
Andrew Liu, M.D., National Jewish Health, Denver
Wayne Shreffler, M.D., Ph.D., Mount Sinai School of Medicine, N.Y.
When: Saturday, Feb. 27, 2010, 12:45 p.m. Central Time
Where: Convention Center, Room B2-2, First Level

Why Bone Abnormalities Occur in People with Rare Immunodeficiency Diseases

Primary immunodeficiency diseases (PIDDs) are caused by innate defects in the cells of the immune system. Often resulting from inherited genetic defects, PIDDs are prominent by the agency of an increased susceptibility to infections and other problems that hold arthritis and other autoimmune diseases, inflammatory bowel illness, deteriorating lung dependent, and flash in the pan to grow. Hyper-immunoglobulin E syndrome (HIES or Job’s syndrome) is a PIDD that affects the immune system and connective tissues. People with HIES can develop boils, lung cysts following pneumony, and bone abnormalities, so as scoliosis and minimal trauma fractures. In this investigation, NIAID investigators examined patients by HIES to identify the molecular factors that result in lower-than-normal bone mineral density and an increased number of bone-degrading cells called osteoclasts.

Title: Oral Abstract Session: Immunodeficiency
Presenter: Gulbu Uzel, M.D., NIAID, NIH, Bethesda, Md.
When: Saturday, Feb. 27, 2010, 2:45 p.m. Central Time
Where: Convention Center, Room 206, Second Level

How Distinct Immune Responses Contribute to Different Types of Food Allergy

Eosinophilic gastrointestinal diseases (EGIDs) and conventional peanut allergy both result from abnormal immune responses to food – yet they are distinct disorders. EGIDs are triggered by a food-induced immune replication that causes white blood cells known as eosinophils to accumulate in the gut. Eosinophils and violence in the tissues resolve in bump, which have power to direction to obstacle to belief swallowing. Peanut allergy is caused by immunoglobulin E (IgE) antibodies, which tell other immune cells to set at liberty chemicals. These chemicals, in turn, can cause the symptoms–hives, difficulty breathing and near the ground blood pressure–associated through an allergic reaction. Both EGIDs and peanut allergy are associated with the activation of a type of immune T organic unit known as a T-helper type 2 (Th2) cell. Th2 cells trigger the IgE produce that results in peanut allergy and the increased eosinophil concentrations associated through EGIDs. NIAID investigators will discuss their efforts to understand why the same type of immune cell can trigger these couple different sustenance allergy disorders.

Title: Oral Abstract Session: Inflammatory Mediators in Allergic Disease
Presenter: Calman Prussin, M.D., NIAID, NIH, Bethesda, Md.
When: Sunday, Feb. 28, 2010, 2:45 p.salmagundi. Central Time
Where: Convention Center, Room 220, Second Level

Oral Immunotherapy Reduces the Immune Response to Egg: Results from a Double-Blind, Placebo-Controlled Trial in Egg-Allergic Children

Food allergy is an immunologic disease that affects an estimated 4.7 percent of children under five years of age and 3.7 percent of children ages 5 to 17 years in the United States. NIAID established the Consortium of Food Allergy Research (CoFAR) to develop new approaches to treat and stop food allergy. In this study, CoFAR investigators tested the safety, efficacy and immunologic effects of using oral immunotherapy to behave to children (ages 5 to 18 years) with egg allergy, one of the most common food allergies in this time arrange. In oral immunotherapy, a bodily form consumes gradually increasing amounts of the fodder allergen in order to reduce the immune response to the regimen, thus increasing the ability to allow larger amounts of the food. The results of the learn indicate a confident clinical efficiency. The ultimate mete is to lay open long-lasting immunologic sufferance so that, even after not eating the aliment for weeks, the bodily form exist possible to eat the food destitute of having an allergic reaction. Results from this and other CoFAR studies will be presented during a press court of justice at the meeting, which will also exist available by wide-awake streaming video (accessible at www.aaaai.org/members/annual_meeting/am2010/). More information about CoFAR may be found at structure.emmes.com/sift/cofar/director.htm.

Title: Late Breaking Oral Abstracts: Clinical Sciences
Presenter: Stacie Jones, M.D., University of Arkansas for Medical Sciences, Little Rock, Ark.
When: Tuesday, Mar. 2, 2010, 2:00 p.m. Central Time
Where: Convention Center, Room R01, Second Level

Title: AAAAI Press Forum: Clinical Research Makes Great Strides in Food Allergy
Presenters: A. Wesley Burks, M.D., Duke University, Durham, N.C.
Hugh Sampson, M.D., Mount Sinai Medical Center, N.Y.
Robert Wood, M.D., Johns Hopkins University, Baltimore
When: Sunday, Feb. 28, 2010, 11:00 a.m. Central Time
Where: Convention Center, Room 224, Second Level

Genetic Variants Associated with Eczema in People of European and African Descent

Atopic dermatitis, furthermore known as eczema, is a chronic derm throw into confusion associated by dry, itchy pelt. People by atopic dermatitis have power to desire scaly lesions that can weep discerning liquid on their face, neck and hands and are prone to constant viral and bacterial skin infections. Severe complications of atopic dermatitis include eczema herpeticum, a skin infection due to herpes virus, and eczema vaccinatum, a hide infection fit to vaccinia venom, the virus used in the vaccine to hinder smallpox. Investigators participating in NIAID’session Atopic Dermatitis and Vaccinia Network (ADVN) are conducting clinical research studies to superior take understanding atopic dermatitis and to identify biomarkers in opposition to those at risk for the complications of eczema herpeticum and eczema vaccinatum. This ADVN investigation describes the role of interferon regulatory factor 2 (IRF2), a protein in immune cells of people with atopic dermatitis that controls the expression of a signaling ultimate particle called interferon-gamma (IFN-?). The results indicate a genetic association between IRF2 and the pair atopic dermatitis and eczema herpeticum. Results testament be described through the head creator of this reflect, Pei-Song Gao, M.D., Ph.D., receiver of the 2010 AAAAI Outstanding Pediatric Allergy, Asthma and Immunology Abstract Award. Additional information on ADVN may exist found at www.nationaljewish.org/advn/alphabetical table of references.aspx.

Title: Oral Abstract Session: Mechanisms of Atopy
Presenter: Pei-Song Gao, M.D., Ph.D., Johns Hopkins Asthma and Allergy Center, Johns Hopkins University, Baltimore
When: Tuesday, Mar. 2, 2010, 2:45 p.mish-mash. Central Time
Where: Convention Center, Room 222, Second Level

What’s New in Drugs, Anaphylaxis and Venom

Anaphylaxis is a severe, potentially life-threatening whole-body allergic reaction to certain allergens, including foods, medications and insect bites or stings. After exposure to these substances, an allergic person may experience abdominal worry or cramping, break out into hives or have difficulty desire. During this sitting, Dean Metcalfe, M.D., chief of NIAID’s Laboratory of Allergic Diseases, will discuss the latest clinical findings concerning the role of mast cells, types of immune cells involved in anaphylaxis and other related allergic disorders and disease. More information attached the work in Dr. Metcalfe’s lab may be found at www.niaid.nih.gov/labs/aboutlabs/lad/.

Title: Workshop: Year-in-Review
Presenter: Dean Metcalfe, M.D., NIAID, NIH, Bethesda, Md.
When: Tuesday, Mar. 2, 2010, 3:55 p.m. Central Time
Where: Convention Center, Rooms R02 and R03, Second Level

Source:
Julie Wu
NIH/National Institute of Allergy and Infectious Diseases

Comments are closed.